Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 11/20 | 0.58 |
| ▸ | MAPT | P10636 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | AR | P10275 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13879514 | 0.96 | ALDH1A1 (0.60) | TSHRALDH1A1MAPTKMT2AAR | |
| SCHEMBL10465001 | 0.91 | ALDH1A1 (0.55) | TSHRALDH1A1MAPTKMT2AAR | |
| SCHEMBL13879532 | 0.85 | KMT2A (0.77) | TSHRALDH1A1MAPTKMT2AAR | |
| SCHEMBL11556670 | 0.82 | KMT2A (0.70) | TSHRALDH1A1MAPTKMT2AKDM4E | |
| SCHEMBL13879494 | 0.81 | KMT2A (0.72) | TSHRALDH1A1MAPTKMT2AAR | |
| SCHEMBL11174171 | 0.81 | AR (0.64) | TSHRALDH1A1MAPTKMT2AAR | |
| SCHEMBL13879545 | 0.81 | AR (0.60) | TSHRALDH1A1KMT2AARPOLB | |
| SCHEMBL12543889 | 0.81 | AR (0.56) | TSHRALDH1A1MAPTKMT2AAR | |
| SCHEMBL5740339 | 0.80 | KMT2A (0.72) | TSHRALDH1A1KMT2AARPOLB | |
| SCHEMBL5739794 | 0.77 | AR (0.67) | ALDH1A1KMT2AARPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090099186-A1 | INHIBITORS OF VIRAL REPLICATION | INTERMUNE, INC. | 2009-04-16 | — | — | US | disclosed |
| US-20090099186-A1 | INHIBITORS OF VIRAL REPLICATION | INTERMUNE, INC. | 2009-04-16 | — | — | US | disclosed |
| WO-2007047146-A2 | INHIBITORS OF VIRAL REPLICATION | INTERMUNE, INC. (US) | 2007-04-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090099186-A1 | INHIBITORS OF VIRAL REPLICATION | EIF2AK2, HAVCR2, RTF2 | TSHR 4851/4885ALDH1A1 1500/4885MAPT 4203/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.